ClinicalTrials.gg
TerminatedNCT06058156ADVANTAUpdated Nov 3, 2026Results posted

Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis

A Phase 2 interventional study of SAR444656 (KT-474) and Placebo in Atopic Dermatitis, sponsored by Sanofi. Terminated at 22 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor decision. Not related to safety concern.
Updated Nov 3, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Dermatitis, Atopic by Sanofi — 5 open to participants now, 16 under way, 4 of them phase 3. Dermatitis, Atopic · Sanofi.

Enrollment
17th of 28
70 · median 112
Started
2023
with 9 others
Phase 2
8 of 43
none open now
Registered
27th of 43
by date

Among the 43 studies in Dermatitis, Atopic by Sanofi, this one is the 17th largest by enrollment of the 28 interventional ones that give a count, is one of 10 that started in 2023, is one of 8 in phase 2, and was the 27th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

5 of the 43 studies in Dermatitis, Atopic by Sanofi are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Dermatitis, Atopic by Sanofi, or all of them as a file.
02

Study summary

This was a multinational, multicenter, double-blind, placebo-controlled, parallel-group Phase 2, 4-arm study in adult participants with moderate to severe AD who were inadequately controlled with topical therapies or for whom such topical therapies were inadvisable and who were candidates for systemic therapy.

Participants were randomized to receive SAR444656 dose 1, dose 2, dose 3 or matching placebo.

Participants who met inclusion/exclusion criteria were stratified for randomization by severity of AD (moderate [baseline EASI score \<22] versus severe [baseline EASI score ≥22]).

The total duration of study was approximately 24 weeks, including 1 to 4 weeks for screening, 16 weeks for double-blind study treatment and 4 weeks for follow-up.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 3, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with atopic dermatitis as defined by the American Academy of Dermatology Consensus Criteria for at least 1 year before the baseline visit.
  • EASI ≥12 at screening and at baseline visit
  • vIGA score ≥3 (on the 0 to 4 IGA scale, in which 3 was moderate and 4 was severe) at screening and baseline visit.
  • AD involvement ≥10% of BSA at screening and baseline visit
  • Baseline PP-NRS ≥4
  • Participants must had documented history within 6 months prior to baseline visit, of either inadequate response or inadvisability to topical medications
  • Participants must had applied daily topical emollient (moisturizer) for at least the 7 consecutive days immediately before the baseline visit. Participants should continued using daily moisturizers during the study.
  • Participants must be willing and completed the electronic diary for the duration of the study as required by the study protocol.
  • used by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  • Presence of other skin conditions that may interfere with study assessments such as psoriasis, tinea corporis, lupus erythematosus
  • Any active or chronic infection requiring systemic treatment within 4 weeks prior to baseline
  • Known history of, or suspected, significant current , including history of invasive opportunistic or helminth infections despite infection resolution or otherwise recurrent infections of abnormal frequency or prolonged duration.
  • History of solid organ or stem cell transplant.
  • Participants with history of splenectomy.
  • Participants with history of any or lymphoproliferative disease, except if the participant has been free from disease for ≥5 years. Successfully treated non- cutaneous squamous cell carcinoma, basal cell carcinoma, or localized carcinoma in situ of the cervix are allowed.
  • Family history of sudden death or long syndrome.
  • History of congenital or drug-induced long QT syndrome.
  • Congestive heart failure ( Class 2-4), greater than Class 1 angina pectoris, acute coronary syndrome within prior 6 months, known structural heart disease.
  • History of any major cardiovascular events (eg, myocardial infarction, unstable angina pectoris, coronary revascularization, stroke, or ) at any time prior to screening.
  • History of ventricular fibrillation, ventricular tachycardia, Torsades de Pointes, atrial fibrillation, syncope not explained by non-cardiac etiology.
  • Uncontrolled hypertension defined as consistent systolic blood pressure ≥150 mm Hg or consistent diastolic blood pressure ≥90 mm Hg despite antihypertensive medication.
  • Participants had major surgery within 4 weeks prior to the screening or have planned any elective major surgery during the study.
  • Having received any of protocol-specified prohibited therapy (Topical or systemic) within the specified timeframe prior to the baseline visit.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo matched to SAR444656 tablet orally from Day 1 to Week 16.

    Drug: Placebo

  • Experimental
    SAR444656 Dose Level 1

    Participants received SAR444656 Dose Level 1 tablet orally from Day 1 to Week 16. Dose Level 1 is the highest dose level.

    Drug: SAR444656 (KT-474)

  • Experimental
    SAR444656 Dose Level 2

    Participants received SAR444656 Dose Level 2 tablet orally from Day 1 to Week 16. Dose Level 2 is the lower dose level.

    Drug: SAR444656 (KT-474)

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Eczema Area and Severity Index at Week 16

    EASI is an Investigator-assessed validated tool to measure extent (area) and severity of AD based on 4 disease characteristics (erythema \[E\], induration/papulation \[I\], excoriation \[X\] and lichenification \[L\]) in 4 different body areas using 4-point scale: 0 (absent) to 3 (severe). Extent of involvement of AD in 4 body regions: head/neck, trunk, UE and LE is assessed. For each region, percentage of body surface area (BSA) is converted to area score: 0=no eruption, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%. EASI score is calculated as: (E+I+X+L) x area score. Total EASI score is the weighted total of region EASI using weights 10% (head/neck), 20% (UE), 30% (trunk) and 40% (LE); ranges from 0 to 72 and higher scores indicate increased extent and severity of AD. Baseline was defined as last available value before the first dose of double-blind study drug.

    Time frame: Baseline (Day 1) and Week 16

Secondary outcomes

  1. Percentage of Participants With Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) of 0 or 1 and a Reduction From Baseline of >=2 Points at Week 16

    The vIGA-AD is an Investigator-led assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale: 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate) and 4 (severe). Higher vIGA-AD scores indicate more severe disease. Percentage of participants with a score of 0 or 1 and a reduction from baseline of \>=2 points at Week 16 are presented here. Baseline was defined as last available value before the first dose of double-blind study drug. Percentages are rounded off to the tenth decimal place.

    Time frame: Baseline (Day 1) and Week 16

  2. Percentage of Participants Achieving 75% Reduction From Baseline in Eczema Area and Severity Index (EASI-75) at Week 16

    EASI is an Investigator-assessed validated tool to measure extent (area) and severity of AD based on 4 disease characteristics (E, I, X and L) in 4 different body areas using 4-point scale: 0 (absent) to 3 (severe). Extent of involvement of AD in 4 body regions: head/neck, trunk, UE and LE is assessed. For each region, percentage of BSA is converted to area score: 0=no eruption, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%. EASI score is calculated as: (E+I+X+L) x area score. Total EASI score is the weighted total of region EASI using weights 10% (head/neck), 20% (UE), 30% (trunk) and 40% (LE); ranges from 0 to 72 and higher scores indicate increased extent and severity of AD. EASI-75 was defined as reduction of EASI score by \>=75% from baseline. Baseline was defined as last available value before the first dose of double-blind study drug. Percentages are rounded off to the tenth decimal place.

    Time frame: Baseline (Day 1) and Week 16

  3. Absolute Change From Baseline in Eczema Area and Severity Index at Week 16

    EASI is an Investigator-assessed validated tool to measure extent (area) and severity of AD based on 4 disease characteristics (E, I, X and L) in 4 different body areas using 4-point scale: 0 (absent) to 3 (severe). Extent of involvement of AD in 4 body regions: head/neck, trunk, UE and LE is assessed. For each region, percentage of BSA is converted to area score: 0=no eruption, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%. EASI score is calculated as: (E+I+X+L) x area score. Total EASI score is the weighted total of region EASI using weights 10% (head/neck), 20% (UE), 30% (trunk) and 40% (LE); ranges from 0 to 72 and higher scores indicate increased extent and severity of AD. Baseline was defined as last available value before the first dose of double-blind study drug.

    Time frame: Baseline (Day 1) and Week 16

  4. Percentage of Participants Achieving 50% Reduction From Baseline in Eczema Area and Severity Index (EASI-50) at Week 16

    EASI is an Investigator-assessed validated tool to measure extent (area) and severity of AD based on 4 disease characteristics (E, I, X and L) in 4 different body areas using 4-point scale: 0 (absent) to 3 (severe). Extent of involvement of AD in 4 body regions: head/neck, trunk, UE and LE is assessed. For each region, percentage of BSA is converted to area score: 0=no eruption, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%. EASI score is calculated as: (E+I+X+L) x area score. Total EASI score is the weighted total of region EASI using weights 10% (head/neck), 20% (UE), 30% (trunk) and 40% (LE); ranges from 0 to 72 and higher scores indicate increased extent and severity of AD. EASI-50 was defined as reduction of EASI score by \>=50% from baseline. Baseline was defined as last available value before the first dose of double-blind study drug. Percentages are rounded off to the tenth decimal place.

    Time frame: Baseline (Day 1) and Week 16

  5. Percentage of Participants Achieving 90% Reduction From Baseline in Eczema Area and Severity Index (EASI-90) at Week 16

    EASI is an Investigator-assessed validated tool to measure extent (area) and severity of AD based on 4 disease characteristics (E, I, X and L) in 4 different body areas using 4-point scale: 0 (absent) to 3 (severe). Extent of involvement of AD in 4 body regions: head/neck, trunk, UE and LE is assessed. For each region, percentage of BSA is converted to area score: 0=no eruption, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%. EASI score is calculated as: (E+I+X+L) x area score. Total EASI score is the weighted total of region EASI using weights 10% (head/neck), 20% (UE), 30% (trunk) and 40% (LE); ranges from 0 to 72 and higher scores indicate increased extent and severity of AD. EASI-90 was defined as reduction of EASI score by \>=90% from baseline. Baseline was defined as last available value before the first dose of double-blind study drug. Percentages are rounded off to the tenth decimal place.

    Time frame: Baseline (Day 1) and Week 16

  6. Change From Baseline in Percent Body Surface Area Affected by Atopic Dermatitis at Week 16

    The BSA affected by AD is assessed by the Investigator for each section of the body. Each body region is weighted using the 'rule of nines': head and neck (9%), anterior trunk (18%), back (18%), upper limbs (18%), lower limbs (36%), and genitals (1%); reported as a percentage of all major body sections combined. Baseline was defined as last available value before the first dose of double-blind study drug.

    Time frame: Baseline (Day 1) and Week 16

  7. Percentage of Participants With >=4-Point Reduction From Baseline in Weekly Average of Daily Peak Pruritus-Numeric Rating Scale (PP-NRS) at Week 16

    The PP-NRS is a validated single item 0-10 numerical rating scale assessing peak pruritus (itch) associated with AD during the past 24 hours. The participant is asked about the severity of his/her pruritus on a 0 to 10 scale, where 0=no itch and 10=worst itch imaginable. Higher scores indicate more severe disease. The weekly average PP-NRS score was calculated as the average of 7 days preceding the actual visit day of measurement with a minimum of 4 completions in their daily diary. Baseline was defined as the average of all available daily non-missing scores obtained during the 7 days prior to randomization. Percentages are rounded off to tenth decimal place.

    Time frame: Baseline (Day 1) and Week 16

  8. Percent Change From Baseline in Weekly Average of Daily Peak Pruritus-Numeric Rating Scale at Week 16

    The PP-NRS is a validated single item 0-10 numerical rating scale assessing peak pruritus (itch) associated with AD during the past 24 hours. The participant is asked about the severity of his/her pruritus on a 0 to 10 scale, where 0=no itch and 10=worst itch imaginable. Higher scores indicate more severe disease. The weekly average PP-NRS score was calculated as the average of 7 days preceding the actual visit day of measurement with a minimum of 4 completions in their daily diary. Baseline was defined as the average of all available daily non-missing scores obtained during the 7 days prior to randomization.

    Time frame: Baseline (Day 1) and Week 16

  9. Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus-Numeric Rating Scale at Week 16

    The PP-NRS is a validated single item 0-10 numerical rating scale assessing peak pruritus (itch) associated with AD during the past 24 hours. The participant is asked about the severity of his/her pruritus on a 0 to 10 scale, where 0=no itch and 10=worst itch imaginable. Higher scores indicate more severe disease. The weekly average PP-NRS score was calculated as the average of 7 days preceding the actual visit day of measurement with a minimum of 4 completions in their daily diary. Baseline was defined as the average of all available daily non-missing scores obtained during the 7 days prior to randomization.

    Time frame: Baseline (Day 1) and Week 16

  10. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Treatment-Emergent Adverse Events of Special Interest (TEAESIs) and TEAEs Leading to Study Drug Discontinuation

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or any other medically important event. A TEAE was an AE that developed, worsened or became serious during the TE period. An AESI was an AE (serious or non-serious) was one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required.

    Time frame: From first dose of study drug (Day 1) up to 20 weeks

  11. Serum Concentrations of SAR444656

    Blood samples were collected at specified timepoints to determine serum concentration of SAR444656.

    Time frame: Pre-dose, 2, 4 and 7 hours post-dose at Weeks 0 and 2; pre-dose and 7 hours post-dose at Weeks 1, 4 and 16

07

Results

Posted Nov 3, 2026
Limitations and caveats
The study was terminated early due to Sponsor decision and not related to safety concerns.

Participant flow

The study was conducted at 20 centers in 4 countries from 09-Nov-2023 to 20-Nov-2025. A total of 70 participants were randomized. Dosing information (dose levels and frequency) has not been disclosed as it is considered as commercially confidential information. Dose levels decrease from 1 to 3, with Dose Level 1 being the highest dose and Dose Level 3 the lowest dose.

Participant flow — Overall Study
MilestonePlaceboSAR444656 Dose Level 1SAR444656 Dose Level 2
Started282814
Completed192010
Not completed984
Withdrew: Adverse event130
Withdrew: Lack of efficacy111
Withdrew: Poor compliance to protocol210
Withdrew: Withdrawal by subject331
Withdrew: Other202

Outcome measures

PrimaryPercent Change From Baseline in Eczema Area and Severity Index at Week 16

EASI is an Investigator-assessed validated tool to measure extent (area) and severity of AD based on 4 disease characteristics (erythema \[E\], induration/papulation \[I\], excoriation \[X\] and lichenification \[L\]) in 4 different body areas using 4-point scale: 0 (absent) to 3 (severe). Extent of involvement of AD in 4 body regions: head/neck, trunk, UE and LE is assessed. For each region, percentage of body surface area (BSA) is converted to area score: 0=no eruption, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%. EASI score is calculated as: (E+I+X+L) x area score. Total EASI score is the weighted total of region EASI using weights 10% (head/neck), 20% (UE), 30% (trunk) and 40% (LE); ranges from 0 to 72 and higher scores indicate increased extent and severity of AD. Baseline was defined as last available value before the first dose of double-blind study drug.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in Eczema Area and Severity Index at Week 16
percent changePlaceboSAR444656 Dose Level 1SAR444656 Dose Level 2
Percent Change From Baseline in Eczema Area and Severity Index at Week 16-31.58 ± 9.08-39.94 ± 10.35-34.16 ± 14.35
SecondaryPercentage of Participants With Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) of 0 or 1 and a Reduction From Baseline of >=2 Points at Week 16

The vIGA-AD is an Investigator-led assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale: 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate) and 4 (severe). Higher vIGA-AD scores indicate more severe disease. Percentage of participants with a score of 0 or 1 and a reduction from baseline of \>=2 points at Week 16 are presented here. Baseline was defined as last available value before the first dose of double-blind study drug. Percentages are rounded off to the tenth decimal place.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) of 0 or 1 and a Reduction From Baseline of >=2 Points at Week 16
percentage of participantsPlaceboSAR444656 Dose Level 1SAR444656 Dose Level 2
Percentage of Participants With Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) of 0 or 1 and a Reduction From Baseline of >=2 Points at Week 1610.725.042.9
SecondaryPercentage of Participants Achieving 75% Reduction From Baseline in Eczema Area and Severity Index (EASI-75) at Week 16

EASI is an Investigator-assessed validated tool to measure extent (area) and severity of AD based on 4 disease characteristics (E, I, X and L) in 4 different body areas using 4-point scale: 0 (absent) to 3 (severe). Extent of involvement of AD in 4 body regions: head/neck, trunk, UE and LE is assessed. For each region, percentage of BSA is converted to area score: 0=no eruption, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%. EASI score is calculated as: (E+I+X+L) x area score. Total EASI score is the weighted total of region EASI using weights 10% (head/neck), 20% (UE), 30% (trunk) and 40% (LE); ranges from 0 to 72 and higher scores indicate increased extent and severity of AD. EASI-75 was defined as reduction of EASI score by \>=75% from baseline. Baseline was defined as last available value before the first dose of double-blind study drug. Percentages are rounded off to the tenth decimal place.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 75% Reduction From Baseline in Eczema Area and Severity Index (EASI-75) at Week 16
percentage of participantsPlaceboSAR444656 Dose Level 1SAR444656 Dose Level 2
Percentage of Participants Achieving 75% Reduction From Baseline in Eczema Area and Severity Index (EASI-75) at Week 1617.925.042.9
SecondaryAbsolute Change From Baseline in Eczema Area and Severity Index at Week 16

EASI is an Investigator-assessed validated tool to measure extent (area) and severity of AD based on 4 disease characteristics (E, I, X and L) in 4 different body areas using 4-point scale: 0 (absent) to 3 (severe). Extent of involvement of AD in 4 body regions: head/neck, trunk, UE and LE is assessed. For each region, percentage of BSA is converted to area score: 0=no eruption, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%. EASI score is calculated as: (E+I+X+L) x area score. Total EASI score is the weighted total of region EASI using weights 10% (head/neck), 20% (UE), 30% (trunk) and 40% (LE); ranges from 0 to 72 and higher scores indicate increased extent and severity of AD. Baseline was defined as last available value before the first dose of double-blind study drug.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · score on a scale
Absolute Change From Baseline in Eczema Area and Severity Index at Week 16
score on a scalePlaceboSAR444656 Dose Level 1SAR444656 Dose Level 2
Absolute Change From Baseline in Eczema Area and Severity Index at Week 16-7.65 ± 10.34-9.68 ± 11.28-9.40 ± 15.55
SecondaryPercentage of Participants Achieving 50% Reduction From Baseline in Eczema Area and Severity Index (EASI-50) at Week 16

EASI is an Investigator-assessed validated tool to measure extent (area) and severity of AD based on 4 disease characteristics (E, I, X and L) in 4 different body areas using 4-point scale: 0 (absent) to 3 (severe). Extent of involvement of AD in 4 body regions: head/neck, trunk, UE and LE is assessed. For each region, percentage of BSA is converted to area score: 0=no eruption, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%. EASI score is calculated as: (E+I+X+L) x area score. Total EASI score is the weighted total of region EASI using weights 10% (head/neck), 20% (UE), 30% (trunk) and 40% (LE); ranges from 0 to 72 and higher scores indicate increased extent and severity of AD. EASI-50 was defined as reduction of EASI score by \>=50% from baseline. Baseline was defined as last available value before the first dose of double-blind study drug. Percentages are rounded off to the tenth decimal place.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 50% Reduction From Baseline in Eczema Area and Severity Index (EASI-50) at Week 16
percentage of participantsPlaceboSAR444656 Dose Level 1SAR444656 Dose Level 2
Percentage of Participants Achieving 50% Reduction From Baseline in Eczema Area and Severity Index (EASI-50) at Week 1646.442.942.9
SecondaryPercentage of Participants Achieving 90% Reduction From Baseline in Eczema Area and Severity Index (EASI-90) at Week 16

EASI is an Investigator-assessed validated tool to measure extent (area) and severity of AD based on 4 disease characteristics (E, I, X and L) in 4 different body areas using 4-point scale: 0 (absent) to 3 (severe). Extent of involvement of AD in 4 body regions: head/neck, trunk, UE and LE is assessed. For each region, percentage of BSA is converted to area score: 0=no eruption, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%. EASI score is calculated as: (E+I+X+L) x area score. Total EASI score is the weighted total of region EASI using weights 10% (head/neck), 20% (UE), 30% (trunk) and 40% (LE); ranges from 0 to 72 and higher scores indicate increased extent and severity of AD. EASI-90 was defined as reduction of EASI score by \>=90% from baseline. Baseline was defined as last available value before the first dose of double-blind study drug. Percentages are rounded off to the tenth decimal place.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 90% Reduction From Baseline in Eczema Area and Severity Index (EASI-90) at Week 16
percentage of participantsPlaceboSAR444656 Dose Level 1SAR444656 Dose Level 2
Percentage of Participants Achieving 90% Reduction From Baseline in Eczema Area and Severity Index (EASI-90) at Week 1610.725.014.3
SecondaryChange From Baseline in Percent Body Surface Area Affected by Atopic Dermatitis at Week 16

The BSA affected by AD is assessed by the Investigator for each section of the body. Each body region is weighted using the 'rule of nines': head and neck (9%), anterior trunk (18%), back (18%), upper limbs (18%), lower limbs (36%), and genitals (1%); reported as a percentage of all major body sections combined. Baseline was defined as last available value before the first dose of double-blind study drug.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · percent BSA
Change From Baseline in Percent Body Surface Area Affected by Atopic Dermatitis at Week 16
percent BSAPlaceboSAR444656 Dose Level 1SAR444656 Dose Level 2
Change From Baseline in Percent Body Surface Area Affected by Atopic Dermatitis at Week 16-8.17 ± 10.92-13.73 ± 16.33-10.74 ± 21.82
SecondaryPercentage of Participants With >=4-Point Reduction From Baseline in Weekly Average of Daily Peak Pruritus-Numeric Rating Scale (PP-NRS) at Week 16

The PP-NRS is a validated single item 0-10 numerical rating scale assessing peak pruritus (itch) associated with AD during the past 24 hours. The participant is asked about the severity of his/her pruritus on a 0 to 10 scale, where 0=no itch and 10=worst itch imaginable. Higher scores indicate more severe disease. The weekly average PP-NRS score was calculated as the average of 7 days preceding the actual visit day of measurement with a minimum of 4 completions in their daily diary. Baseline was defined as the average of all available daily non-missing scores obtained during the 7 days prior to randomization. Percentages are rounded off to tenth decimal place.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With >=4-Point Reduction From Baseline in Weekly Average of Daily Peak Pruritus-Numeric Rating Scale (PP-NRS) at Week 16
percentage of participantsPlaceboSAR444656 Dose Level 1SAR444656 Dose Level 2
Percentage of Participants With >=4-Point Reduction From Baseline in Weekly Average of Daily Peak Pruritus-Numeric Rating Scale (PP-NRS) at Week 167.114.842.9
SecondaryPercent Change From Baseline in Weekly Average of Daily Peak Pruritus-Numeric Rating Scale at Week 16

The PP-NRS is a validated single item 0-10 numerical rating scale assessing peak pruritus (itch) associated with AD during the past 24 hours. The participant is asked about the severity of his/her pruritus on a 0 to 10 scale, where 0=no itch and 10=worst itch imaginable. Higher scores indicate more severe disease. The weekly average PP-NRS score was calculated as the average of 7 days preceding the actual visit day of measurement with a minimum of 4 completions in their daily diary. Baseline was defined as the average of all available daily non-missing scores obtained during the 7 days prior to randomization.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in Weekly Average of Daily Peak Pruritus-Numeric Rating Scale at Week 16
percent changePlaceboSAR444656 Dose Level 1SAR444656 Dose Level 2
Percent Change From Baseline in Weekly Average of Daily Peak Pruritus-Numeric Rating Scale at Week 16-16.39 ± 32.26-10.93 ± 36.39-28.19 ± 43.68
SecondaryAbsolute Change From Baseline in Weekly Average of Daily Peak Pruritus-Numeric Rating Scale at Week 16

The PP-NRS is a validated single item 0-10 numerical rating scale assessing peak pruritus (itch) associated with AD during the past 24 hours. The participant is asked about the severity of his/her pruritus on a 0 to 10 scale, where 0=no itch and 10=worst itch imaginable. Higher scores indicate more severe disease. The weekly average PP-NRS score was calculated as the average of 7 days preceding the actual visit day of measurement with a minimum of 4 completions in their daily diary. Baseline was defined as the average of all available daily non-missing scores obtained during the 7 days prior to randomization.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · score on a scale
Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus-Numeric Rating Scale at Week 16
score on a scalePlaceboSAR444656 Dose Level 1SAR444656 Dose Level 2
Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus-Numeric Rating Scale at Week 16-0.90 ± 1.68-0.85 ± 2.24-2.53 ± 3.23
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Treatment-Emergent Adverse Events of Special Interest (TEAESIs) and TEAEs Leading to Study Drug Discontinuation

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or any other medically important event. A TEAE was an AE that developed, worsened or became serious during the TE period. An AESI was an AE (serious or non-serious) was one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required.

Time frame:
From first dose of study drug (Day 1) up to 20 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Treatment-Emergent Adverse Events of Special Interest (TEAESIs) and TEAEs Leading to Study Drug Discontinuation
ParticipantsPlaceboSAR444656 Dose Level 1SAR444656 Dose Level 2
Any TEAE10208
Any TESAE020
Any TEAESI020
Any TEAE Leading to Study Drug Discontinuation130
SecondarySerum Concentrations of SAR444656

Blood samples were collected at specified timepoints to determine serum concentration of SAR444656.

Time frame:
Pre-dose, 2, 4 and 7 hours post-dose at Weeks 0 and 2; pre-dose and 7 hours post-dose at Weeks 1, 4 and 16
Reported as:
Mean · nanogram per milliliter
Serum Concentrations of SAR444656
nanogram per milliliterSAR444656 Dose Level 1SAR444656 Dose Level 2
Week 0: Pre-dose0.00 ± 0.000.00 ± 0.00
Week 0: 2 hours post-dose6.08 ± 5.892.72 ± 3.15
Week 0: 4 hours post-dose8.50 ± 8.054.65 ± 5.28
Week 0: 7 hours post-dose9.90 ± 8.695.39 ± 5.64
Week 1: Pre-dose9.76 ± 6.534.04 ± 3.20
Week 1: 7 hours post-dose16.13 ± 8.697.70 ± 5.45
Week 2: Pre-dose8.86 ± 6.554.03 ± 2.35
Week 2: 2 hours post-dose14.38 ± 10.756.98 ± 3.79
Week 2: 4 hours post-dose16.94 ± 11.887.88 ± 4.67
Week 2: 7 hours post-dose15.60 ± 9.458.38 ± 3.78
Week 4: Pre-dose8.60 ± 7.903.44 ± 2.61
Week 4: 7 hours post-dose13.28 ± 8.367.19 ± 5.28
Week 16: Pre-dose6.68 ± 8.612.65 ± 1.84
Week 16: 7 hours post-dose19.17 ± 10.533.73 ± 2.25

Adverse events

Collected over AEs were collected from first dose of study drug (Day 1) up to 20 weeks. All-cause mortality (deaths) was collected from first dose of study drug (Day 1) up to study termination, up to approximately 106 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/28 (0%)0/28 (0%)4/28 (14.3%)
SAR444656 Dose Level 10/28 (0%)2/28 (7.1%)11/28 (39.3%)
SAR444656 Dose Level 20/14 (0%)0/14 (0%)8/14 (57.1%)
Most frequent serious events
Most frequent serious events
EventPlaceboSAR444656 Dose Level 1SAR444656 Dose Level 2
Abdominal PainGastrointestinal disorders0/281/280/14
Abortion SpontaneousPregnancy, puerperium and perinatal conditions0/281/280/14
Maternal Exposure During PregnancyInjury, poisoning and procedural complications0/281/280/14
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPlaceboSAR444656 Dose Level 1SAR444656 Dose Level 2
HeadacheNervous system disorders0/287/282/14
Dermatitis AtopicSkin and subcutaneous tissue disorders4/280/282/14
InfluenzaInfections and infestations0/282/280/14
NasopharyngitisInfections and infestations1/281/281/14
Urinary Tract InfectionInfections and infestations0/282/280/14
Bowen's DiseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/280/281/14
DizzinessNervous system disorders0/281/281/14
MicrosleepNervous system disorders0/280/281/14
SyncopeNervous system disorders0/280/281/14
AsthmaRespiratory, thoracic and mediastinal disorders0/280/281/14

Baseline characteristics

The efficacy population included all randomized participants who took at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboSAR444656 Dose Level 1SAR444656 Dose Level 2Total
Mean34.6 ± 12.239.7 ± 16.243.9 ± 15.038.5 ± 14.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSAR444656 Dose Level 1SAR444656 Dose Level 2Total
Female1618842
Male1210628
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboSAR444656 Dose Level 1SAR444656 Dose Level 2Total
Caucasian22201254
Black or African American56112
Asian0202
Not Reported0011
Eczema Area and Severity Index (EASI)
Eczema Area and Severity Index (EASI)(score on a scale)PlaceboSAR444656 Dose Level 1SAR444656 Dose Level 2Total
Mean21.6 ± 11.023.1 ± 9.521.8 ± 7.622.2 ± 9.7
08

Study locations

22 sites
  • Encore Medical Research of Boynton Beach- Site Number : 8400002
    Boynton Beach, Florida 33436, United States
  • Revival Research - Doral- Site Number : 8400007
    Doral, Florida 33122, United States
  • Encore Medical Research - 6600 Taft St- Site Number : 8400004
    Hollywood, Florida 33024, United States
  • Sullivan Dermatology- Site Number : 8400001
    Miami, Florida 33162, United States
  • Encore Medical Research - Weston- Site Number : 8400008
    Weston, Florida 33331, United States
  • Wayne Health - Dearborn- Site Number : 8400009
    Dearborn, Michigan 48126, United States
  • UPMC Montefiore- Site Number : 8400006
    Pittsburgh, Pennsylvania 15213, United States
  • Investigational Site Number : 2760009
    Munich, Bavaria 80337, Germany
  • Investigational Site Number : 2760008
    Frankfurt am Main, Hesse 60590, Germany
  • Investigational Site Number : 2760002
    Buxtehude, Lower Saxony 21614, Germany
  • Investigational Site Number : 2760003
    Bochum, North Rhine-Westphalia 44791, Germany
  • Investigational Site Number : 2760006
    Remscheid, North Rhine-Westphalia 42897, Germany
  • Investigational Site Number : 2760001
    Berlin, 13353, Germany
  • Investigational Site Number : 3000002
    Thessaloniki, 546 43, Greece
  • Investigational Site Number : 6160006
    Tarnów, Lesser Poland Voivodeship 33-100, Poland
  • Investigational Site Number : 6160012
    Wroclaw, Lower Silesian Voivodeship 50-449, Poland
  • Investigational Site Number : 6160002
    Wroclaw, Lower Silesian Voivodeship 50-566, Poland
  • Investigational Site Number : 6160007
    Warsaw, Masovian Voivodeship 00-874, Poland
  • Investigational Site Number : 6160005
    Warsaw, Masovian Voivodeship 02-758, Poland
  • Investigational Site Number : 6160003
    Chojnice, Pomeranian Voivodeship 89-600, Poland
  • Investigational Site Number : 6160004
    Gdansk, Pomeranian Voivodeship 80-546, Poland
  • Investigational Site Number : 6160009
    Katowice, Silesian Voivodeship 40-040, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Oct 2025, 23 months.

Results were first posted in Nov 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2023
First posted
Sep 28, 2023
StartActual
Nov 9, 2023
Primary completionActual
Oct 23, 2025
CompletionActual
Nov 20, 2025
Results first posted
Nov 3, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 3, 2026
Sites
15 sites removed; no longer in Czechia and South Korea
Show 15 removed
  • Clear Dermatology & Aesthetics Center- Site Number : 8400003 · Scottsdale, United States
  • ARA Professionals- Site Number : 8400017 · Miami, United States
  • ACRC Trials - Carrollton - Hunt - PPDS- Site Number : 8400012 · Carrollton, United States
  • Investigational Site Number : 2030002 · Ostrava, Czechia
  • Investigational Site Number : 2030001 · Pardubice, Czechia
  • Investigational Site Number : 2030003 · Prague, Czechia
  • Investigational Site Number : 2760007 · Heidelberg, Germany
  • Investigational Site Number : 2760010 · Dessau, Germany
  • Investigational Site Number : 3000001 · Pavlos Melas, Greece
  • Investigational Site Number : 6160011 · Lodz, Poland
  • Investigational Site Number : 6160001 · Lodz, Poland
  • Investigational Site Number : 6160010 · Lodz, Poland
  • Investigational Site Number : 4100002 · Cheonan-si, South Korea
  • Investigational Site Number : 4100001 · Ansan-si, South Korea
  • Investigational Site Number : 4100004 · Seongbuk-Gu, South Korea
Nov 3, 2026
Eligibility
5 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedvIGA score ≥3 (on the 0 to 4 IGA scale, in which 3 iswas moderate and 4 iswas severe) at screening and baseline visit.
  • EditedParticipants must havehad documented history within 6 months prior to baseline visit, of either inadequate response or inadvisability to topical medications
  • EditedParticipants must havehad applied daily topical emollient (moisturizer) for at least the 7 consecutive days immediately before the baseline visit. Participants should continuecontinued using daily moisturizers during the study.
  • EditedParticipants must be willing and able to completecompleted the electronic diary for the duration of the study as required by the study protocol.
  • EditedContraceptive useused by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Nov 3, 2026
Interventions
Arm changed SAR444656 dose 1→SAR444656 Dose Level 1; SAR444656 dose 2→SAR444656 Dose Level 2. Arms removed: SAR444656 dose 3
Nov 3, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedPercent change from baselineChange From Baseline in EASIEczema Area and Severity Index at Week 16Time frame: Week 16 → Baseline (Day 1) and Week 16
Nov 3, 2026
Documents
Secondary outcomes
7 edited, 4 added, 4 removed
What changed in the outcomes
  • EditedProportionPercentage of participants with validated InvestigationalParticipants With Validated Investigator Global Assessment-Atopic Dermatitis (vIGA)-AD) of 0 or 1 and a reduction from baselineReduction From Baseline of ≥>=2 pointsPoints at Week 16Time frame: Week 16 → Baseline (Day 1) and Week 16
  • EditedAbsolute change from baselineChange From Baseline in EASIEczema Area and Severity Index at Week 16Time frame: Week 16 → Baseline (Day 1) and Week 16
  • EditedChange from baselineFrom Baseline in percent body surface area (BSA) affectedPercent Body Surface Area Affected by ADAtopic Dermatitis at Week 16Time frame: Week 16 → Baseline (Day 1) and Week 16
  • EditedProportionPercentage of participants with reductionParticipants With >=4-Point Reduction From Baseline in Weekly Average of weekly average of daily peak pruritus numeric rating scaleDaily Peak Pruritus-Numeric Rating Scale (PP-NRS) by ≥4 points from baselineat Week 16Time frame: Week 16 → Baseline (Day 1) and Week 16
  • EditedPercent change from baselineChange From Baseline in weekly averageWeekly Average of daily PPDaily Peak Pruritus-NRSNumeric Rating Scale at Week 16Time frame: Week 16 → Baseline (Day 1) and Week 16
  • EditedAbsolute change from baselineChange From Baseline in weekly averageWeekly Average of daily PPDaily Peak Pruritus-NRSNumeric Rating Scale at Week 16Time frame: Week 16 → Baseline (Day 1) and Week 16
  • EditedIncidenceNumber of treatmentParticipants With Treatment-emergent adverse eventsEmergent Adverse Events (TEAEs), serious adverse eventsTreatment-Emergent Serious Adverse Events (SAEsTESAEs), and adverse eventsTreatment-Emergent Adverse Events of special interestSpecial Interest (AESIs), investigational medicinal product (IMPTEAESIs) discontinuation dueand TEAEs Leading to TEAEsStudy Drug DiscontinuationTime frame: Up to Week 20 → From first dose of study drug (Day 1) up to 20 weeks
  • AddedPercentage of Participants Achieving 75% Reduction From Baseline in Eczema Area and Severity Index (EASI-75) at Week 16Time frame: Baseline (Day 1) and Week 16
  • AddedPercentage of Participants Achieving 50% Reduction From Baseline in Eczema Area and Severity Index (EASI-50) at Week 16Time frame: Baseline (Day 1) and Week 16
  • AddedPercentage of Participants Achieving 90% Reduction From Baseline in Eczema Area and Severity Index (EASI-90) at Week 16Time frame: Baseline (Day 1) and Week 16
  • AddedSerum Concentrations of SAR444656Time frame: Pre-dose, 2, 4 and 7 hours post-dose at Weeks 0 and 2; pre-dose and 7 hours post-dose at Weeks 1, 4 and 16
  • RemovedProportion of participants achieving EASI-75 (reduction of EASI score by ≥75% from baseline)Time frame: Week 16
  • RemovedProportion of participants achieving EASI-50 (reduction of EASI score by ≥50% from baseline)Time frame: Week 16
  • RemovedProportion of participants achieving EASI-90 (reduction of EASI score by ≥90% from baseline)Time frame: Week 16
  • RemovedPlasma SAR444656 concentrationTime frame: Week 0, Week 1, Week 2, Week 4, and Week 16
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Results posted
    15 sites removed; no longer in Czechia and South Korea
    Show 15 removed
    • Clear Dermatology & Aesthetics Center- Site Number : 8400003 · Scottsdale, United States
    • ARA Professionals- Site Number : 8400017 · Miami, United States
    • ACRC Trials - Carrollton - Hunt - PPDS- Site Number : 8400012 · Carrollton, United States
    • Investigational Site Number : 2030002 · Ostrava, Czechia
    • Investigational Site Number : 2030001 · Pardubice, Czechia
    • Investigational Site Number : 2030003 · Prague, Czechia
    • Investigational Site Number : 2760007 · Heidelberg, Germany
    • Investigational Site Number : 2760010 · Dessau, Germany
    • Investigational Site Number : 3000001 · Pavlos Melas, Greece
    • Investigational Site Number : 6160011 · Lodz, Poland
    • Investigational Site Number : 6160001 · Lodz, Poland
    • Investigational Site Number : 6160010 · Lodz, Poland
    • Investigational Site Number : 4100002 · Cheonan-si, South Korea
    • Investigational Site Number : 4100001 · Ansan-si, South Korea
    • Investigational Site Number : 4100004 · Seongbuk-Gu, South Korea
    Eligibility 5 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedvIGA score ≥3 (on the 0 to 4 IGA scale, in which 3 iswas moderate and 4 iswas severe) at screening and baseline visit.
    • EditedParticipants must havehad documented history within 6 months prior to baseline visit, of either inadequate response or inadvisability to topical medications
    • EditedParticipants must havehad applied daily topical emollient (moisturizer) for at least the 7 consecutive days immediately before the baseline visit. Participants should continuecontinued using daily moisturizers during the study.
    • EditedParticipants must be willing and able to completecompleted the electronic diary for the duration of the study as required by the study protocol.
    • EditedContraceptive useused by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPercent change from baselineChange From Baseline in EASIEczema Area and Severity Index at Week 16Time frame: Week 16 → Baseline (Day 1) and Week 16
    Secondary outcomes 7 edited, 4 added, 4 removed
    What changed in the outcomes
    • EditedProportionPercentage of participants with validated InvestigationalParticipants With Validated Investigator Global Assessment-Atopic Dermatitis (vIGA)-AD) of 0 or 1 and a reduction from baselineReduction From Baseline of ≥>=2 pointsPoints at Week 16Time frame: Week 16 → Baseline (Day 1) and Week 16
    • EditedAbsolute change from baselineChange From Baseline in EASIEczema Area and Severity Index at Week 16Time frame: Week 16 → Baseline (Day 1) and Week 16
    • EditedChange from baselineFrom Baseline in percent body surface area (BSA) affectedPercent Body Surface Area Affected by ADAtopic Dermatitis at Week 16Time frame: Week 16 → Baseline (Day 1) and Week 16
    • EditedProportionPercentage of participants with reductionParticipants With >=4-Point Reduction From Baseline in Weekly Average of weekly average of daily peak pruritus numeric rating scaleDaily Peak Pruritus-Numeric Rating Scale (PP-NRS) by ≥4 points from baselineat Week 16Time frame: Week 16 → Baseline (Day 1) and Week 16
    • EditedPercent change from baselineChange From Baseline in weekly averageWeekly Average of daily PPDaily Peak Pruritus-NRSNumeric Rating Scale at Week 16Time frame: Week 16 → Baseline (Day 1) and Week 16
    • EditedAbsolute change from baselineChange From Baseline in weekly averageWeekly Average of daily PPDaily Peak Pruritus-NRSNumeric Rating Scale at Week 16Time frame: Week 16 → Baseline (Day 1) and Week 16
    • EditedIncidenceNumber of treatmentParticipants With Treatment-emergent adverse eventsEmergent Adverse Events (TEAEs), serious adverse eventsTreatment-Emergent Serious Adverse Events (SAEsTESAEs), and adverse eventsTreatment-Emergent Adverse Events of special interestSpecial Interest (AESIs), investigational medicinal product (IMPTEAESIs) discontinuation dueand TEAEs Leading to TEAEsStudy Drug DiscontinuationTime frame: Up to Week 20 → From first dose of study drug (Day 1) up to 20 weeks
    • AddedPercentage of Participants Achieving 75% Reduction From Baseline in Eczema Area and Severity Index (EASI-75) at Week 16Time frame: Baseline (Day 1) and Week 16
    • AddedPercentage of Participants Achieving 50% Reduction From Baseline in Eczema Area and Severity Index (EASI-50) at Week 16Time frame: Baseline (Day 1) and Week 16
    • AddedPercentage of Participants Achieving 90% Reduction From Baseline in Eczema Area and Severity Index (EASI-90) at Week 16Time frame: Baseline (Day 1) and Week 16
    • AddedSerum Concentrations of SAR444656Time frame: Pre-dose, 2, 4 and 7 hours post-dose at Weeks 0 and 2; pre-dose and 7 hours post-dose at Weeks 1, 4 and 16
    • RemovedProportion of participants achieving EASI-75 (reduction of EASI score by ≥75% from baseline)Time frame: Week 16
    • RemovedProportion of participants achieving EASI-50 (reduction of EASI score by ≥50% from baseline)Time frame: Week 16
    • RemovedProportion of participants achieving EASI-90 (reduction of EASI score by ≥90% from baseline)Time frame: Week 16
    • RemovedPlasma SAR444656 concentrationTime frame: Week 0, Week 1, Week 2, Week 4, and Week 16
    Interventions Arm changed SAR444656 dose 1→SAR444656 Dose Level 1; SAR444656 dose 2→SAR444656 Dose Level 2. Arms removed: SAR444656 dose 3
    + 3 other changes: identifiers, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06058156
Lead sponsor
Sanofi
Collaborators
Kymera Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 28, 2023
Start date
Nov 9, 2023
Primary completion
Oct 23, 2025
Completion
Nov 20, 2025
Results posted
Nov 3, 2026
Last update
Nov 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tipasertideg

Start the discussion